DEFA14A: Alcon to Acquire STAAR Surgical for $1.5 Billion

Alcon has entered into a definitive merger agreement to acquire STAAR Surgical Company for $28.00 per share in cash, valuing the company at approximately $1.5 billion.

Summary

• Alcon Research, LLC will acquire STAAR Surgical Company through a merger, with STAAR Surgical becoming a wholly owned subsidiary of Alcon.
• Each outstanding share of STAAR common stock will be converted into the right to receive $28.00 in cash.
• The transaction represents a total equity value of approximately $1.5 billion.
• The per-share price of $28.00 represents a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to its closing price on August 4, 2025.
• STAAR's Board of Directors unanimously approved the merger agreement and recommends stockholders adopt it.
• The merger is subject to stockholder approval, regulatory approvals (including HSR Act), and other customary closing conditions.
• Financing for the transaction is not a condition to the merger; Alcon intends to use shortand long-term credit facilities.
• The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to Alcon's earnings in year two.

Sentiment

Score: 9

Explanation: The sentiment is highly positive for STAAR shareholders due to the substantial premium offered. For Alcon, it represents a strategic acquisition that is expected to be accretive and expand its market presence in a growing segment of eye care.

Positives

• STAAR shareholders will receive an immediate and certain cash value of $28.00 per share, representing a significant premium of 59% to the 90-day VWAP and 51% to the August 4, 2025 closing price.
• The acquisition by Alcon, a global leader in eye care, is expected to accelerate the adoption of STAAR's innovative EVO ICL technology globally due to Alcon's capabilities and scale.
• The transaction is complementary to Alcon's existing laser vision correction business, allowing for a broader offering across the myopia treatment spectrum.
• The merger is expected to be accretive to Alcon's earnings in year two, indicating a positive financial outlook for the combined entity.

Negatives

• STAAR's CEO noted that fluctuating demand in China over the past two years has created significant headwinds for STAAR as a standalone company, indicating challenges prior to the merger announcement.

Risks

• The proposed merger may not be completed in a timely manner or at all, including risks related to obtaining required regulatory approvals or stockholder approval.
• Anticipated benefits of the proposed merger may not be fully realized.
• There is a possibility of competing offers or acquisition proposals for STAAR.
• Third parties and/or STAAR stockholders may oppose the consummation of the proposed merger.
• Any or all of the various conditions to the consummation of the merger may not be satisfied or waived.
• The merger may result in the diversion of management's time and attention from ongoing business operations.
• The announcement or pendency of the merger could affect STAAR's ability to retain and hire key personnel or maintain relationships with customers, suppliers, or distributors.
• STAAR's stock price may decline significantly if the merger is not consummated.
• Legal proceedings may be instituted against STAAR following the announcement of the merger, which may have an unfavorable outcome.

Future Outlook

The acquisition is expected to enhance Alcon's ability to offer a leading surgical vision correction solution for patients not ideal for LASIK, providing treatment options across the full spectrum of myopia. The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to Alcon's earnings in year two. STAAR's CEO believes Alcon's scale will accelerate EVO ICL adoption globally.

Management Comments

• David Endicott, CEO of Alcon: "This transaction will allow us to provide treatment options across the full spectrum of myopia—from contact lenses to surgical interventions—reinforcing our commitment to addressing the most significant needs in eye care."
• Stephen Farrell, CEO of STAAR: "We believe the transaction with Alcon represents the best path forward and provides the greatest value for STAAR shareholders... Fluctuating demand in China over the past two years has continued to create significant headwinds for STAAR as a standalone company... Alcon has the capabilities and scale to accelerate EVO ICL adoption and bring our innovative technology to more surgeons and patients worldwide."
• Dr. Elizabeth Yeu, Chair of the STAAR Board of Directors: "This carefully negotiated transaction is in the best interest of STAAR shareholders as it delivers immediate and certain value at a significant premium, value that exceeds what we believe could be achieved under STAARs standalone strategy."

Industry Context

The acquisition positions Alcon, a global leader in eye care, to expand its offerings in refractive surgery, specifically for moderate to high myopia, complementing its existing laser vision correction business. This move addresses the rising global prevalence of myopia, with an estimated 50% of the world expected to be myopic by 2050, including nearly 500 million high myopes today. STAAR's EVO ICL technology offers a minimally invasive, reversible solution for vision correction without removing corneal tissue, providing a distinct offering in the market.

Corporate Governance

Legal Proceedings

• The filing mentions the possibility of legal proceedings being instituted against STAAR following the announcement of the merger, which may have an unfavorable outcome.
• STAAR is obligated to promptly notify Alcon of any stockholder litigation and allow Alcon to participate in its defense, prosecution, settlement, or compromise, and to consult with legal counsel.

Stakeholder Impact

• Shareholders: Will receive a significant cash premium for their shares, providing immediate liquidity and value realization.
• Employees: Continuing employees will receive comparable base salary/wage, target annual cash bonus opportunities, and substantially comparable aggregate employee benefits for one year post-closing. Service credit for new plans and waiver of certain waiting periods are also provided. STAAR's 401(k) plan may be terminated with rollover options.
• Customers, Suppliers, and Distributors: The announcement and pendency of the merger could impact existing relationships, though Alcon's scale is expected to accelerate EVO ICL adoption.
• Directors and Officers: Current and former directors and officers will retain indemnification rights and D&O insurance coverage for six years post-merger.

Next Steps

• STAAR Surgical will establish a record date, call, give notice of, convene, and hold a stockholder meeting to vote on the adoption of the Merger Agreement.
• STAAR Surgical will file a proxy statement on Schedule 14A with the SEC.
• The companies will work to obtain all necessary regulatory approvals, including the expiration or termination of the HSR Act waiting period.
• STAAR Surgical's common stock will be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934 after the merger's effective time.
• STAAR Surgical will release its second quarter financial results on August 6, 2025, but will not host a conference call due to the pending acquisition.

Key Dates

Recommendation

The filing details a definitive merger agreement where STAAR Surgical shareholders will receive $28.00 per share in cash. This represents a substantial premium of 59% over the 90-day VWAP and 51% over the previous day's closing price. For existing shareholders, this offers an immediate and significant return on investment. The unanimous board approval and the strategic fit with Alcon, a major industry player, further de-risk the transaction, making it a strong buy for investors looking to capitalize on the announced premium.

Keywords

Merger, Acquisition, STAAR Surgical, Alcon, Ophthalmology, Implantable Collamer Lens, ICL, Myopia, Refractive Surgery, Medical Devices, Eye Care, Stock Acquisition